Navigation Links
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
Date:11/6/2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that data relevant to betrixaban, the company's novel oral Factor Xa inhibitor and PRT060128, its novel ADP receptor antagonist, will be presented at the American Heart Association (AHA) Scientific Sessions 2008. The conference will be held at the Ernest N. Morial Convention Center in New Orleans, LA during November 8-12, 2008.

"We have important data being presented at AHA that demonstrate the potential of our differentiated Phase II compounds that address major unmet needs in preventing and treating thrombosis," said Charles Homcy, M.D., president and chief executive officer of Portola. "In particular, data from Dr. Paul Gurbel show how our antiplatelet agent may be effective in a high percentage of patients who do not respond adequately to clopidogrel, the current standard of care. Additionally, data being presented will show that our two Phase II agents, PRT060128 and betrixaban, our oral once-daily FXa inhibitor, may work in combination to inhibit thrombosis without raising bleeding risk. Together these data highlight some of the unique properties of our lead antithrombotic compounds."

Following are the details on each poster presentation.

Monday, November 10

Poster Title: "Combination of Direct Acting FXa Inhibitor and P2Y12

Antagonist at Non-Effective Doses Provides Significant Inhibition of

Arterial Thrombosis"

Patrick Andre et al

Time: 9:00 a.m. - 5:00 p.m.

Hall A-B1, Poster Board B129

Wednesday, November 12

Poster Title: "Oral Dosing of PRT060128, a Novel Direct-acting,

Reversible P2Y12 Antagonist Overcomes High Platelet Reactivity in

Patients Non-responsive to Clopidogrel Therapy"

Paul A. Gurbel et al

Time: 9:00 a.m. - 5:00 p.m.

Hall A-B1, Poster Board C6

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http://www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017  US medical equipment and supply ... according to Medical Equipment & Supplies: United ... Focus Reports. Continued increases in demand for medical services ... the population and supported by gains in disposable personal ... supplies. New product introductions will also drive sales as ...
(Date:7/6/2017)... ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, is ... nutrition support. To celebrate its anniversary, ThriveRx recently launched a ... new look with improved organization to create the best user experience for ... ... "We,ve made several great strides ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is ... product of her research center at Bio-Logic Aqua Research® Water Life Science®, has ... greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network ... quality of life a decade after surgery, though activity levels decline over time. ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... concussion rates are on the rise, say researchers presenting their work at the ... Ontario, Canada. , “The combination of evaluating the patterns of change in concussion ...
(Date:7/20/2017)... Richmond, Va. (PRWEB) , ... July 20, 2017 , ... ... Daniel McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief ... of Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
Breaking Medicine News(10 mins):